De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat

Neurobiology of Disease

Volumn 34, Issue 2, 2009, Pages 340-350

  Atifi Borel, Michèle El ^a   Buggia Prevot, Virginie ^a   Platet, Nadine ^a   Benabid, Alim Louis ^a,b   Berger, François ^a,c   Sgambato Faure, Véronique ^a,d  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

6 hydroxydopamine; Dyskinesia; Microarray; Parkinson's disease; Striatum; Transcriptome

Indexed keywords

BENSERAZIDE; LEVODOPA; OXIDOPAMINE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EXOCYTOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PARKINSON DISEASE; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SECRETION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TRANSCRIPTOMICS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CELL PROLIFERATION; CORPUS STRIATUM; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; LEVODOPA; MALE; NERVE REGENERATION; NEUROGENESIS; NEURONAL PLASTICITY; NEUROTOXINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 64649106413     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.02.002     Document Type: Article

References (44)

1. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6 (1999) 461-474
2. Barbeau A. l-Dopa therapy in Parkinson's disease: a critical review of nine years experience. Can. Med. Assoc. J. 101 (1969) 791-800
3. Bassilana F., Mace N., Li Q., Stutzmann J.M., Gross C.E., Pradier L., Benavides J., Ménager J., and Bezard E. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol. Dis. 20 (2005) 93-103
4. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4 (2004) 3943-3952
5. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., and Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 18 (1998) 5301-5310
6. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2 (2001) 577-588
7. Blanchet P.J., Calon F., Morissette M., Hadj Tahar A., Bélanger N., Samadi P., Grondin R., Grégoire L., Meltzer L., Di Paolo T., and Bédard P.J. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat. Disord. 10 (2004) 297-304
8. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 30 (2007) 236-243
9. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
10. Chase T.N. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat. Disord. 10 (2004) 305-313
11. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Wokosin D., Ilijic E., Sun Z., Sampson A.R., Mugnaini E., Deutch A.Y., Sesack S.R., Arbuthnott G.W., and Surmeier D.J. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci. 9 (2006) 251-259
12. De Iuliis A., Grigoletto J., Recchia A., Giusti P., and Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin. Chim. Acta 357 (2005) 202-209
13. Defebvre L. Motor complications in dopa treatment of parkinson disease: clinical description and evaluation. Thérapie 59 (2004) 93-96
14. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14863-14868
15. El Atifi M., Dupré I., Rostaing B., Chambaz E.M., Benabid A.L., and Berger F. Long oligonucleotide arrays on nylon for large-scale gene expression analysis. Biotechniques 33 (2002) 612-618
16. El Atifi M., Dupré I., Rostaing B., Benabid A.L., and Berger F. Quantification of DNA probes on nylon microarrays using T4 polynucleotide kinase labeling. Biotechniques 35 (2003) 262-266
17. Ferrario J.E., Taravini I.R., Mourlevat S., Stefano A., Delfino M.A., Raisman-Vozari R., Murer M.G., Ruberg M., and Gershanik O. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J. Neurochem. 90 (2004) 1348-1358
18. Filion M. Physiological basis of dyskinesia. Ann. Neurol. 47 (2000) S35-S40
19. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22 (2002) 5042-5054
20. Grünblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., Li J., Ravid R., Roggendorf W., Riederer P., and Youdim M.B. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111 (2004) 1543-1573
21. Hess E.J., Collins K.A., and Wilson M.C. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J. Neurosci. 16 (1996) 3104-3111
22. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9 (2008) 665-677
23. Konradi C., Westin J.E., Carta M., Eaton M.E., Kuter K., Dekundy A., Lundblad M., and Cenci M.A. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 17 (2004) 219-236
24. Kühn K., Wellen J., Link N., Maskri L., Lübbert H., and Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17 (2003) 1-12
25. Kultima K., Scholz B., Alm H., Sköld K., Svensson M., Crossman A.R., Bezard E., Andrén P.E., and Lönnstedt I. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of l-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinformatics 7 (2006) 475
26. Mandel S., Weinreb O., and Youdim M.B. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol. Sci. 24 (2003) 184-191
27. Mansuy I.M., and Shenolikar S. Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory. Trends Neurosci. 29 (2006) 679-686
28. Meng Y., Zhang Y., Tregoubov V., Falls D.L., and Jia Z. Regulation of spine morphology and synaptic function by LIMK and the actin cytoskeleton. Rev. Neurosci. 14 (2003) 233-240
29. Miranda E., and Lomas D.A. Neuroserpin: a serpin to think about. Cell. Mol. Life Sci. 63 (2006) 709-722
30. Mirnics K., and Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat. Neurosci. 7 (2004) 434-439
31. Morelli M., Cozzolino A., Pinna A., Fenu S., Carta A., and Di Chiara G. l-dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors. Brain Res. 623 (1993) 334-336
32. Obeso J.A., Rodríguez-Oroz M.C., Rodríguez M., Lanciego J.L., Artieda J., Gonzalo N., and Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23 (2000) S8-S19
33. Obeso J.A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J.L., and Rodriguez-Diaz M. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 (2004) S17-S30
34. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., and Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 6 (2003) 501-506
35. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., and Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 323 (2007) 277-284
36. Scarr E., Gray L., Keriakous D., Robinson P.J., and Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord. 8 (2006) 133-143
37. Scholz B., Svensson M., Alm H., Sköld K., Fälth M., Kultima K., Guigoni C., Doudnikoff E., Li Q., Crossman A.R., Bezard E., and Andrén P.E. Striatal proteomic analysis suggests that first l-dopa dose equates to chronic exposure. PLoS ONE 3 (2008) e1589
38. Sgambato-Faure V., Buggia V., Gilbert F., Lévesque D., Benabid A.L., and Berger F. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with l-dopa-induced behavioral sensitization in dyskinetic rats. J. Neuropathol. Exp. Neurol. 64 (2005) 936-947
39. Smith R., Klein P., Koc-Schmitz Y., Waldvogel H.J., Faull R.L., Brundin P., Plomann M., and Li J.Y. Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. J. Neurochem. 103 (2007) 115-123
40. Solis O., Limón D.I., Flores-Hernández J., and Flores G. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse 61 (2007) 450-458
41. Szumlinski K.K., Kalivas P.W., and Worley P.F. Homer proteins: implications for neuropsychiatric disorders. Curr. Opin. Neurobiol. 16 (2006) 251-257
42. Szumlinski K.K., Ary A.W., and Lominac K.D. Homers regulate drug-induced neuroplasticity: implications for addiction. Biochem. Pharmacol. 75 (2008) 112-133
43. Tzingounis A.V., and Nicoll R.A. Arc/Arg3.1: linking gene expression to synaptic plasticity and memory. Neuron 52 (2006) 403-407
44. Valastro B., Dekundy A., Krogh M., Lundblad M., James P., Danysz W., Quack G., and Cenci M.A. Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia. J. Neurochem. 102 (2007) 1395-1409